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Chronic kidney diseases (CKDs) are the most common forms of kidney disease all around the world. The incidence
of CKD is rising, which is mainly driven by population aging as well as by a global rise in hypertension, metabolic
syndrome, and metabolic risk factors, particularly obesity and type-2 diabetes. The high mortality, morbidity of
CKD, and the health care costs of the renal replacement therapy have led investigators to seek recent and potentially
modiﬁable risk factors such as non-alcoholic fatty liver disease (NAFLD). NAFLD is the hepatic manifestation of
metabolic syndrome and the most common cause of chronic liver disease. It incorporates a spectrum of liver diseases
ranging from simple steatosis to steatohepatitis, liver cirrhosis, and hepatocellular carcinoma. On the basis of recent
publications, the prevalence of CKD is signiﬁcantly increased among patients with NAFLD, and the prevalence
of NAFLD is also higher in CKD patients than in patients without NAFLD. These ﬁndings suggest that patients
with NAFLD should be screened for CKD and patients with CKD and metabolic syndrome should be screened for
NAFLD. Patients with NAFLD and CKD should be treated and followed up by a multidisciplinary team that involves
specialists in hepatology, nephrology, diabetes, and cardiology.
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Introduction
Kidney disease is a global public health problem affecting >25% of individuals above the age
of 65 years in the adult Western population affecting more than 750 million people worldwide
(8, 19). Nowadays, chronic kidney diseases (CKDs) are the most common forms of kidney
disease, with an estimated prevalence of about 10.4% among men and 11.8% among women all
around the world (12). All recently published data seem to indicate that the incidence of CKD is
rising (11, 25) and there are international differences in CKD prevalence (3).
The analysis of the data demonstrates that the growing burden of CKD is mainly driven
by population aging as well as by a global rise in metabolic syndrome and metabolic risk
factors, particularly obesity and type-2 diabetes (11).
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Diagnosis of CKD
CKD is deﬁned by the presence of decreased glomerular ﬁltration rate (eGFR < 60 ml/min/
1.73 m2) and/or by evidence of structural and functional abnormalities of the kidneys
noted on urine examination (mainly albuminuria/proteinuria), imaging or histology of renal
biopsies, which are present for more than 3 months. A ﬁve-stage classiﬁcation system of
CKD is devised internationally to guide rating of the severity of CKD cases (14, 15). The
ﬁve-stage system is based on eGFR (Table I).
GFR is estimated from a single serum creatinine measurement using creatinine-based
eGFR equations, from which the CKD epidemiology collaboration (CKD-EPI) equation
(epiGFR) is the best accepted at present.
CKD may progress to end-stage renal disease (ESRD). The number of patients requiring
renal replacement therapy due to ESRD varies from <30 to >200 persons per million
population across European countries, and is much higher in high-income countries (17).
Furthermore, the cardiovascular morbidity and mortality of CKD patients is also high.
The major risk factors for the progression of CKD are hypertension, proteinuria,
smoking, insulin resistance, and some of the components of metabolic syndrome, such as
abdominal obesity, type-2 diabetes mellitus, dyslipidemia, and hyperuricemia. The high
mortality and morbidity of CKD and the costs of renal replacement therapies (hemodialysis,
peritoneal dialysis, and transplantation) have led investigators to seek potentially modiﬁable
risk factors. A risk factor is a variable that has a causal association with a disease; the presence
of the variable in an individual or a population is associated with an increased risk of the
presence or future development of a disease (30). One of the recently recognized risk factors
is non-alcoholic fatty liver disease (NAFLD) (18).
NAFLD
NAFLD is the hepatic manifestation of metabolic syndrome and the most common cause of
chronic liver disease worldwide (10, 18). It is a condition characterized by the accumulation
of fat in the liver of people who drink minimal or no alcohol at all and who do not have
alternate causes for hepatic steatosis (such as viral infection, drug intoxication, iron overload,
or autoimmune disease) (6, 32). NAFLD incorporates a spectrum of liver diseases ranging
from simple steatosis to steatohepatitis [non-alcoholic steatohepatitis (NASH)], liver
Table I. Classiﬁcation of chronic kidney diseases (CKD) by glomerular ﬁltration rate (GFR)
Stage Description GFR (ml/min)
1 Kidney damage with normal or elevated GFR >90
2 Kidney damage with mild decrease of GFR 60–89
3a Kidney damage with mildly to moderately decreased GFR 45–59
3b Kidney damage with moderately to severely decreased GFR 30–44
4 Severe decrease of GFR 29–15
5 End-stage renal failure <15
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cirrhosis, and hepatocellular carcinoma (33). The global prevalence of NAFLD is approxi-
mately 25%–30% (36). In Europe, the prevalence is between 2% and 44% in the general
population (2). The huge variation in the prevalence can be explained by the multitude of
methods used for the diagnosis of NAFLD. However, the prevalence is as high as 24%–
69.5% in patients with diabetes mellitus (31, 34).
Diagnosis of NAFLD
Laboratory abnormalities
Mildly to moderately elevated levels of serum liver enzymes (aminotransferases and
gamma-glutamyltransferase) are the most common and the only laboratory abnormalities
frequently found in patients with NAFLD. However, serum liver enzyme levels are not
reliable indicators for the diagnosis of NAFLD, as there is no biochemical abnormality in
most patients with a spectrum of NAFLD (6).
Imaging
The liver ultrasonography is the recommended ﬁrst-line examination for the detection of
NAFLD in the clinical practice (9). On ultrasound, hepatic steatosis produces a typical diffuse
increase in echogenicity (13). The sensitivity and speciﬁcity of the method is approximately
85% and 95%, if the fat inﬁltration of the liver is at least 20%–30%. The method is relatively
inexpensive and could help to exclude other causes of liver disease (1, 13).
Histological examination of liver biopsy
The liver biopsy is the standard procedure for diagnosing NASH and for staging the degree of
inﬂammation and ﬁbrosis in patients with more advanced NAFLD (6, 9). However, the
method is invasive, potentially risky, and patient unfriendly. For this reason, non-invasive
biomarker tests such as NAFLD ﬁbrosis scan and the ﬁbrosis-4 score have been introduced to
use them instead of liver biopsy (5).
Relationship Between CKD and NAFLD
CKD in NAFLD
It is now increasingly clear that NAFLD not only affects the liver but can also increase the
risk of developing extrahepatic diseases, including cardiovascular diseases and CKD (32).
The recent large meta-analysis of Mantovani et al. (18) demonstrated that NAFLD is
signiﬁcantly associated with a 20%–55% increase in the long-term risk of incident CKD
(CKD stage≥ 3) during follow-up of 96,595 adult individuals. However, an important
limitation of this meta-analysis is that no studies with liver biopsy-proven NAFLD were
available. NAFLD was diagnosed only by biochemistry, fatty liver index, or ultrasonogra-
phy. Furthermore, in these studies, creatinine-based equations were used to estimate GFR,
which do not perform well in patients with liver cirrhosis and obesity. Direct measurement of
GFR would give more correct results in these patients. In a previous smaller meta-analysis of
partly liver biopsy-proven NAFLD, Musso et al. (21) demonstrated the existence of a higher
risk of incident CKD in patients with NASH and advanced ﬁbrosis compared to simple
steatosis and non-advanced ﬁbrosis.
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NAFLD in CKD
Patients with CKD are known to have high cardiovascular risk. A recent analysis of 1,148
CKD patients showed that the prevalence of NAFLD was 17.9% in this population and
NAFLD proved to be a strong independent risk factor for cardiovascular events (7).
Pathophysiological interrelationships between the liver and the kidney
A number of environmental and physiological factors can promote the development of
NAFLD. The most common cause of NAFLD is an excessive caloric intake that exceeds
caloric expenditure, resulting in a consequential spillover of surplus energy in the form of
non-esteriﬁed fatty acids from expanded visceral adipose tissue into ectopic fat depots, such
as the liver (32).
The amount of hepatic lipids increases in NAFLD, but the most important is the
triglyceride accumulation in the liver. Approximately, 60% of hepatic lipid is derived from
increased peripheral lipolysis of triglycerides.
The kidney and the liver share a number of pathophysiological pathways that are
intrinsically linked to each other (14, 35). NAFLD, especially NASH with or without some
degree of liver ﬁbrosis, may promote the elevation of blood pressure, may induce dyslipidemia
with atherosclerosis, may exacerbate hepatic insulin resistance through the secretion of different
hepatokines (e.g., ﬁbroblast growth factor 21 and fetuin-A), and may release several pro-
inﬂammatory molecules (e.g., tumor necrosis factor-α, C-reactive protein, and interleukin 6),
prooxidants (e.g., reactive oxygen species), procoagulant factors (e.g., ﬁbrinogen and plasmin-
ogen activator inhibitor-1), and proﬁbrogenic factors (e.g., transforming growth factor-β and
connective tissue growth factor). These factors and molecules may play an important role in the
pathophysiology of CKD and other vascular complications (20, 22, 24, 32).
Other risk factors for NAFLD also have the potential to inﬂuence the development of
CKD. Increased intake of dietary fructose, decreased vitamin D3 level, abdominal adiposity,
and insulin resistance can also promote the development of NAFLD and contribute to the
development of CKD (16). Dietary fructose (particularly, the glucose–fructose syrup in sugar
drinks) has become a major public health issue, because it not only increases the hepatic
de novo lipogenesis contributing to the development of NAFLD, but also increases the level
of serum uric acid (27, 28). The increased urinary excretion of uric acid in patients with
hyperuricemia can damage the kidney causing CKD in some of the patients (28).
The gut microbiota may be signiﬁcantly altered in patients with CKD along with
impaired intestinal barrier function. These alterations allow translocation of various gut-
derived products into the systemic circulation, contributing to the development and progres-
sions of CKD (29). In obese and type-2 diabetic patients, the intestinal dysbiosis is common
and can also potentially inﬂuence NAFLD and CKD through multiple and complex
mechanisms (4, 23, 26).
Conclusions
The liver and kidney share a number of pathophysiological pathways that are intrinsically
linked to each other. NAFLD is the most frequent chronic liver disease in the Western society
and its prevalence is likely to rise even further. It is not only a potentially progressive liver
disease but also has systemic consequences. For example, the prevalence of CKD is
signiﬁcantly increased among patients with NAFLD. On the basis of a recent examination,
the prevalence of NAFLD is higher in advanced CKD patients than in patients without CKD.
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On the whole, these ﬁndings suggest that patients with NAFLD should be screened for
CKD with CKD-EPI GFR and with urine examination for proteinuria/albuminuria. Similarly,
patients with CKD and metabolic syndrome should be screened for NAFLD with liver
enzymes and hepatic ultrasonography. At present, there is no accepted treatment for NAFLD,
but lifestyle changes (e.g., weight loss with diet and increased physical activity), nephro-
protective diet, drug dosage adjustment to kidney function, and early aggressive treatment of
all the existing cardiovascular risk factors may help to prevent or slow down the development
and/or progression of CKD in NAFLD patients. Targher and Byrne (32) suggest that patients
with NAFLD and CKD should be treated and followed up by a multidisciplinary team that
includes specialists in hepatology, nephrology, diabetes, and cardiology.
REFERENCES
1. Ballestri S, Nascimbeni F, Baldelli E, Marrazzo A, Romagnoli D, Targher G, Lonardo A: Ultrasonographic fatty
liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver
diseases. Metabolism 72, 57–65 (2017)
2. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F: The burden of liver disease in
Europe: a review of available epidemiological data. J. Hepatol. 58, 593–608 (2013)
3. Brück K, Stel VS, Gambaro G, Hallan S, Völzke H, Ärnlöv J, Kastarinen M, Guessous I, Vinhas J, Stengel B,
Brenner H, Chudek J, Romundstad S, Tomson C, Gonzalez AO, Bello AK, Ferrieres J, Palmieri L, Browne G,
Capuano V, Van Biesen W, Zoccali C, Gansevoort R, Navis G, Rothenbacher D, Ferraro PM, Nitsch D, Wanner
C, Jager KJ; European CKD Burden Consortium: CKD prevalence varies across the European general
population. J. Am. Soc. Nephrol. 27, 2135–2147 (2016)
4. Boursier J, Mueller O, Barret M, Machado M, Fizanne L, Araujo-Perez F, Guy CD, Seed PC, Rawls JF, David
LA, Hunault G, Oberti F, Calès P, Diehl AM: The severity of nonalcoholic fatty liver disease is associated with
gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 63, 764–775 (2016)
5. Castera L, Vilgrain V, Angulo P: Noninvasive evaluation of NAFLD. Nat. Rev. Gastroenterol. Hepatol. 10,
666–675 (2013)
6. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ: The diagnosis and
management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of
Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
Hepatology 55, 2005–2023 (2012)
7. Chinnadurai R, Ritchie J, Green D, Kalra PA: Non-alcoholic fatty liver disease and clinical outcomes in chronic
kidney disease. Nephrol. Dial. Transpl. 34, 449–457 (2019)
8. Crews DC, Bello AK, Saadi G, World Kidney Day Steering Committee: Burden, access, and disparities in
kidney disease. Kidney Int. 95, 242–248 (2019)
9. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes
(EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice
guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 64, 1388–1402 (2016)
10. Fazel Y, Koenig AB, Sayiner M, Goodman ZD, Younossi ZM: Epidemiology and natural history of non-
alcoholic fatty liver disease. Metabolism 65, 1017–1025 (2016)
11. Fraser SDS, Roderick PJ: Kidney disease in the Global Burden of Disease Study 2017. Nat. Rev. Nephrol. 15,
193–194 (2019)
12. GBD 2013 Mortality and Causes of Death Collaborators: Global, regional, and national age–sex speciﬁc all-
cause and cause-speciﬁc mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global
Burden of Disease Study 2013. Lancet 385, 117–171 (2015)
13. Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, Clark JM: Diagnostic accuracy and
reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 54, 1082–1090 (2011)
14. James MT, Hemmelgarn BR, Tonelli M: Early recognition and prevention of chronic kidney disease. Lancet
375, 1296–1309 (2010)
15. Kiapidou S, Liava C, Kalogirou M, Akriviadis E, Sinakos E: Chronic kidney disease in patients with non-
alcoholic fatty liver disease: what the hepatologist should know? Ann. Hepatol. (2019) [Epub ahead of print]
Interrelationships between CKD and NAFLD 309
Physiology International (Acta Physiologica Hungarica) 106, 2019
16. Kovesdy CP, Furth S, Zoccali C, World Kidney Day Steering Committee: Obesity and kidney disease: hidden
consequences of the epidemic. Physiol. Int. 104, 1–14 (2017)
17. Kramer A, Pippias M, Stel VS, Bonthuis M, Abad Diez JM, Afentakis N, Alonso de la Torre R, Ambuhl P,
Bikbov B, Bouzas Caaman˜o E, Bubic I, Buturovic-Ponikvar J, Caskey FJ, Castro de la Nuez P, Cernevskis H,
Collart F, Comas Farnés J, Garcia Bazaga Mde L, De Meester J, Ferrer Alamar M, Finne P, Garneata L, Golan E,
G Heaf J, Hemmelder M, Ioannou K, Kantaria N, Kolesnyk M, Kramar R, Lassalle M, Lezaic V, Lopot F,
Macário F, Magaz A, Martín-Escobar E, Metcalfe W, Ots-Rosenberg M, Palsson R, Pin˜era Celestino C, Resic´ H,
Rutkowski B, Santiuste de Pablos C, Spustová V, Stendahl M, Strakosha A, Süleymanlar G, Torres Guinea M,
Varberg Reisæter A, Vazelov E, Ziginskiene E, Massy ZA, Wanner C, Jager KJ, Noordzij M: Renal replacement
therapy in Europe: a summary of the 2013 ERA-EDTA Registry Annual Report with a focus on diabetes
mellitus. Clin. Kidney J. 9, 457–469 (2016)
18. Mantovani A, Zaza G, Byrne CD, Lonardo A, Zoppini G, Bonora E, Targher G: Nonalcoholic fatty liver disease
increases risk of incident chronic kidney disease: a systematic review and meta-analysis. Metabolism 79, 64–76
(2018)
19. McCullough K, Sharma P, Ali T, Khan I, Smith WC, MacLeod A, Black C: Measuring the population burden of
chronic kidney disease: a systematic literature review of the estimated prevalence of impaired kidney function.
Nephrol. Dial. Transplant. 27, 1812–1821 (2012)
20. Meex RCR, Watt MJ: Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. Nat. Rev.
Endocrinol. 13, 509–520 (2017)
21. Musso G, Gambino R, Tabibian JH, Ekstedt M, Kechagias S, HamaguchiM, Hultcrantz R, HagströmH, Yoon SK,
Charatcharoenwitthaya P, George J, Barrera F, Haﬂiðado´ttir S, Björnsson ES, Armstrong MJ, Hopkins LJ, Gao X,
Francque S, Verrijken A, Yilmaz Y, Lindor KD, Charlton M, Haring R, Lerch MM, Rettig R, Völzke H, Ryu S, Li
G, Wong LL, Machado M, Cortez-Pinto H, Yasui K, Cassader M: Association of non-alcoholic fatty liver disease
with chronic kidney disease: a systematic review and meta-analysis. PLoS Med. 11, e1001680 (2014)
22. Musso G, Cassader M, Cohney S, De Michieli F, Pinach S, Saba F, Gambino R: Fatty liver and chronic kidney
disease: novel mechanistic insights and therapeutic opportunities. Diabetes Care 39, 1830–1845 (2016)
23. Nallu A, Sharma S, Ramezani A, Muralidharan J, Raj D: Gut microbiome in chronic kidney disease: challenges
and opportunities. Transl. Res. 179, 24–37 (2017)
24. Petersen MC, Shulman GI: Roles of diacylglycerols and ceramides in hepatic insulin resistance. Trends
Pharmacol. Sci. 38, 649–665 (2017)
25. Said A, Desai C, Lerma EV: Chronic kidney disease. Dis. Mon. 61, 374–377 (2015)
26. Sampaio-Maia B, Simoes-Silva L, Pestana M, Araujo R, Soares-Silva IJ: The role of the gut microbiome on
chronic kidney disease. Adv. Appl. Microbiol. 96, 65–94 (2016)
27. Scorletti E, Calder PC, Byrne CD: Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects
and novel treatments. Endocrine 40, 332–343 (2011)
28. Softic S, Cohen DE, Kahn CR: Role of dietary fructose and hepatic de novo lipogenesis in fatty liver disease.
Dig. Dis. Sci. 61, 1282–1293 (2016)
29. Sumida K, Kovesdy CP. The gut-kidney-heart axis in chronic kidney disease. Physiol. Int. 106, 195–206 (2019)
30. Taal MW (2012): Risk factors and chronic kidney disease. In: Brenner & Rector’s The Kidney, eds Taal MW,
Chertow GM, Marsden PA, Skorecki K, Yu ASL, Brenner BM, Elsevier, Philadelphia, pp. 758–777
31. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, Day C, Arcaro G: Prevalence of
nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients.
Diabetes Care 30, 1212–1218 (2007)
32. Targher G, Byrne CD: Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease.
Nat. Rev. Nephrol. 13, 297–310 (2017)
33. Vernon G, Baranova A, Younossi ZM: Systematic review: the epidemiology and natural history of non-alcoholic
fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther. 34, 274–285 (2011)
34. Williamson RM, Price JF, Glancy S, Perry E, Nee LD, Hayes PC, Frier BM, Van Look LA, Johnston GI,
Reynolds RM, Strachan MW: Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver
disease in people with type 2 diabetes: the Edinburgh type 2 diabetes study. Diabetes Care 34, 1139–1144 (2011)
35. Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY, Chim AM, Yu J, Sung JJ, Chan HL: Disease
progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 59,
969–974 (2010)
36. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M: Global epidemiology of nonalcoholic
fatty liver disease – meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73–84
(2016)
310 Nagy and Kovács
Physiology International (Acta Physiologica Hungarica) 106, 2019
